• Vaccine Name: M-M-R II
• Target Pathogen: Mumps virus
• Target Disease: Mumps
• Product Name: Measles, Mumps, and Rubella Virus Vaccine, Live
• Tradename: M-M-R II
• Manufacturer: Merck & Co., Inc.
• Vaccine Ontology ID: VO_0000069
• CDC CVX code: 03
• Type: Live, attenuated vaccine
• Status: Licensed
• Location Licensed: USA (License #0002)
• Host Species for Licensed Use: Human
• Preparation: The growth medium for measles and mumps in this vaccine is Medium 199 (a buffered salt solution containing vitamins and amino acids and supplemented with fetal bovine serum) containing SPGA (sucrose, phosphate, glutamate, and recombinant human albumin) as stabilizer and neomycin (FDA: MMR-II).
• Immunization Route: Intramuscular injection (i.m.)
• Storage: 2 to 8°C (36 to 46°F) or colder. Do not freeze.
• Approved Age for Licensed Use: 12 months or older
• Contraindication: Hypersensitivity to any component of the vaccine, a history of anaphylactic or anaphylactoid reactions to neomycin.
• Description: M-M-R II is a sterile lyophilized preparation of (1) ATTENUVAX* (Measles Virus Vaccine Live), a more attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture; (2) MUMPSVAX* (Mumps Virus Vaccine Live), the Jeryl Lynn** (B level) strain of mumps virus propagated in chick embryo cell culture; and (3) MERUVAX* II (Rubella Virus Vaccine Live), the Wistar RA 27/3 strain of live attenuated rubella virus propagated in WI-38 human diploid lung fibroblasts (FDA: MMR-II).

Human Response

• Immune Response: Neutralizing and ELISA antibodies to measles, mumps, and rubella viruses are still detectable in most individuals 11 to 13 years after primary vaccination (FDA: MMR-II).
• Side Effects: Side effects of vaccination are: fever, headache, dizziness, and irritability
• Efficacy: Many clinical studies have shown the vaccine have a high rate of efficacy protection after vaccination with MMR-II (FDA: MMR-II).